drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An anti-CD38 human IgG1 monoclonal antibody given intravenously (16 mg/kg weekly for 8 weeks) to deplete CD38-expressing plasma cells via ADCC, CDC, ADCP and apoptosis, thereby reducing pathogenic autoantibodies driving Evans syndrome.
nci_thesaurus_concept_id
C74007
nci_thesaurus_preferred_term
Daratumumab
nci_thesaurus_definition
A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.
drug_mesh_term
Daratumumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-CD38 human IgG1 monoclonal antibody that binds CD38 on plasma cells and other CD38+ immune cells and mediates Fc-dependent cytotoxicity (ADCC, CDC, ADCP) and apoptosis, depleting CD38-expressing cells and reducing pathogenic autoantibodies.
drug_name
Daratumumab
nct_id_drug_ref
NCT06014775